Financial report context:
vertex pharmaceuticals incorporated notes to consolidated financial statements ( continued ) f . marketable securities ( continued ) unrealized losses in the portfolio relate to various debt securities including u.s . government securities , u.s . government-sponsored enterprise securities , corporate debt securities and asset-backed securities . for these securities , the unrealized losses are primarily due to increases in interest rates . the investments held by the company are high investment grade and there were no adverse credit events . because the company has the ability and intent to hold these investments until a recovery of fair value , which may be maturity , the company does not consider these investments to be other-than-temporarily impaired as of december 31 , 2006 and 2005 . gross realized gains and losses for 2006 were $ 4000 and $ 88000 respectively . gross realized gains and losses for 2005 were $ 15000 and $ 75000 , respectively . gross realized gains and losses for 2004 were $ 628000 and $ 205000 , respectively . g . restricted cash at december 31 , 2006 and 2005 , the company held $ 30.3 million and $ 41.5 million respectively , in restricted cash . at december 31 , 2006 and 2005 the balance was held in deposit with certain banks predominantly to collateralize conditional stand-by letters of credit in the names of the company 2019s landlords pursuant to certain operating lease agreements . h . property and equipment property and equipment consist of the following at december 31 ( in thousands ) : depreciation and amortization expense for the years ended december 31 , 2006 , 2005 and 2004 was $ 25.4 million , $ 26.3 million and $ 28.4 million , respectively . in 2006 and 2005 , the company wrote off certain assets that were fully depreciated and no longer utilized . there was no effect on the company 2019s net property and equipment . additionally , the company wrote off or sold certain assets that were not fully depreciated . the net loss on disposal of those assets was $ 10000 for 2006 , $ 344000 for 2005 and $ 43000 for 2004 . i . altus investment altus pharmaceuticals , inc . ( 201caltus 201d ) completed an initial public offering in january 2006 . as of the completion of the offering , vertex owned 817749 shares of common stock and warrants to purchase 1962494 shares of common stock ( the 201caltus warrants 201d ) . in addition , the company , as of the completion .

Financial table:
2006: furniture and equipment; 2005: $ 97638; column_3: $ 98387
2006: leasehold improvements; 2005: 74875; column_3: 66318
2006: computers; 2005: 19733; column_3: 18971
2006: software; 2005: 21274; column_3: 18683
2006: total property and equipment gross; 2005: 213520; column_3: 202359
2006: less accumulated depreciation and amortization; 2005: 151985; column_3: 147826
2006: total property and equipment net; 2005: $ 61535; column_3: $ 54533

Additional report context:
furniture and equipment $ 97638 $ 98387 leasehold improvements 74875 66318 computers 19733 18971 software 21274 18683 total property and equipment , gross 213520 202359 less accumulated depreciation and amortization 151985 147826 total property and equipment , net $ 61535 $ 54533 .

Question: what was the percent change in depreciation and amortization expense between 2004 and 2005?
Answer: -7.4%